Overview

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Status:
Completed

Trial end date:
2021-06-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Collaborator:

Orion Corporation, Orion Pharma